Filgrastim

• Phase2, double-blind, randomized, placebo-controlled, multicentre study to evaluation the safety, efficacy, and pharmacokinetics of TAK-242 … Not authorised
  2022-501026-37-00 Phase II 3 countries Alpha Bioresearch S.L.; Yaqrit Limited
• Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending
  2023-503676-25-01 Phase II 1 country Azienda Provinciale Per I Servizi Sanitari
• DALY II USA/MB-CART2019.1 for DLBCL Pending
  2023-508508-39-01 Phase II 2 countries Miltenyi Biomedicine GmbH
• Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending
  2024-517295-37-00 Phase III 1 country University Of Cologne
• PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending
  2025-521371-31-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Res… Pending
  2025-524232-20-00 Phase I (FiH) 1 country Asso De Recherche Cancers Gynecologiques
• International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and … Recruiting
  2024-515245-42-00 Phase I (Other) 4 countries GPOH gGmbH
• Stem cell transplantation in diffuse cutaneous systemic sclerosis: upfront therapy or rescue therapy after failure of immunosuppressants Recruiting
  2023-505877-34-00 Phase IV 3 countries University Medical Center Utrecht
• A safety and efficacy study of RTX001 autologous macrophage therapy in participants with decompensated liver cirrhosis Recruiting
  2024-516288-10-00 Phase I/II 1 country Resolution Therapeutics Limited
• SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting
  2023-508260-30-01 Phase III 3 countries Arcagy Gineco
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting
  2023-505436-35-00 Phase III 6 countries Lysarc
• Study to compare the activation of the immune system depending on the chemotherapy scheme used together with PEMBROLIZUM (immunotherapy) in … Recruiting
  2023-507008-30-00 Phase II 1 country Champalimaud Clinical Centre
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl… Recruiting
  2022-500031-37-00 Phase III 7 countries University College London
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 Phase II 5 countries Klinikum Der Universitat Munchen AöR
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
• Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leuke… Recruiting
  2024-514688-24-00 Phase I/II 1 country Heinrich-Heine-Universitaet Duesseldorf
• A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Prog… Recruiting
  2024-514641-12-00 Phase III 2 countries Vertex Pharmaceuticals Inc.
• The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine k… Recruiting
  2023-510240-20-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting
  2022-501180-40-00 Phase III 8 countries GPOH gGmbH
• A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemi… Recruiting
  2024-513349-35-00 Phase III 2 countries Vertex Pharmaceuticals Inc.
• Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes) Recruiting
  2024-515275-35-00 Phase II/III 1 country Hospices Civils De Lyon
• Comparison of Cyclophosphamide and doxorubicin as a first line treatment in elderly patients with metastatic sarcoma Recruiting
  2024-510653-10-00 Phase III 1 country Unicancer
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended
  2022-502975-45-00 Phase III 9 countries Pharma Mar S.A.

Showing 1–24 of 34 trials